Please login to the form below

Not currently logged in

Intellectual property

This page shows the latest Intellectual property news and features for those working in and with pharma, biotech and healthcare.

As May delays, industry warns again of ‘no-deal’ Brexit

As May delays, industry warns again of ‘no-deal’ Brexit

regulation, cross border movement of goods, comparative pricing and intellectual property.”.

Latest news

More from news
Approximately 4 fully matching, plus 254 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 31 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest from PMHub

  • Random42 appoints Bill Collis as Chairman

    He has vast experience in venture capital and private equity funding, intellectual property licensing, mergers and acquisitions and accessing international markets.

  • Indians scalp cowboys in patent war

    The case may open up lots of creative ways for innovative pharmaceutical companies to protect their intellectual property.

  • Biosimilars: Getting the flock to market

    Patents were protected and intellectual property was defended. This is hardly surprising, as billions are at stake - Remicade alone earned Johnson &Johnson over $6bn a year, while Humira is responsible for

  • Exploring MINT: Part 3 - Nigeria

    Regulation of drugs is weak and intellectual property laws are lax. Drugs not officially registered in the country frequently find their way in and the counterfeit drug industry is sizeable.

  • Exploring MINT: Part 1 - Mexico

    Mexico’s pharmaceutical regulator, COFEPRIS, has also implemented measures to improve transparency and has improved the conditions around intellectual property to eliminate ‘similares’ - non bioequivalent ‘copy’ drugs - from the market. .

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...